S. Scott

Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer

F. Meric-Bernstam, N. Ueno, A. González-Angulo, 2017, Breast Cancer Research.

Abstract 4970: Oxidative phosphorylation as a target in triple negative breast cancer therapy

C. Perou, G. Hortobagyi, V. Valero, 2017 .

A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors

G. Mills, F. Meric-Bernstam, Ken Chen, 2017, Clinical Cancer Research.

Combining Neratinib with CDK4/6, mTOR, and MEK Inhibitors in Models of HER2-positive Cancer

F. Meric-Bernstam, Anil Korkut, S. Kopetz, 2021, Clinical Cancer Research.

Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer

F. Meric-Bernstam, N. Ueno, A. González-Angulo, 2017, Breast Cancer Research.

Abstract 4038: Exploring optimal targeted combination therapies with neratinib for HER2+ breast cancer

F. Meric-Bernstam, S. Piha-Paul, Ming Zhao, 2017 .

PDXNet portal: patient-derived Xenograft model, data, workflow and tool discovery

Yvonne A. Evrard, David M. Rocke, Jessica J. Andrews, 2022, NAR cancer.